HOUSTON, Nov. 2 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX)
today announced another in a series of collaborations around seizure detection
technology aimed at advancing its development of new and more efficacious
medical devices for persons suffering from epilepsy.
On October 19, 2009, Cyberonics entered into two agreements with Flint Hills
Scientific L.L.C., a world leader in real-time detection and quantification of
epileptic seizures through cardiac signal detection and processing. The
agreements include a license under certain patents and patent applications,
along with an option to license related inventions, and a framework for
collaborative research and product development. The license agreement
provides for up-front and annual payments, as well as future royalty payments
based on net sales of licensed products.
Earlier last month, Cyberonics announced two collaborations in the field of
EEG-based seizure detection.
"The agreements with Flint Hills Scientific, together with our other
collaborations, demonstrate our commitment to developing new medical devices
that incorporate cutting edge technology to provide improved device solutions
for persons suffering from epilepsy," said Dan Moore, President and Chief
Executive Officer. "We plan to provide more details on our future products at
the Investor Day program scheduled for December 4, 2009 in Boston.
"We are excited about the opportunity to continue to work to improve the lives
of patients with epilepsy."
About Cyberonics, Inc. and VNS Therapy((TM))
Cyberonics, Inc. (NASDAQ:CYBX) is a medical technology company with core
expertise in neuromodulation. The company developed and markets the Vagus
Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the
treatments of refractory epilepsy and treatment-resistant depression. The VNS
Therapy System uses a surgically implanted medical device that delivers pulsed
electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy
System in selected markets worldwide.
Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at
www.cyberonics.com and www.vnstherapy.com.
Safe harbor statement
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements can be
identified by the use of forward-looking terminology, including "may,"
"believe," "will," "expect," "anticipate," "estimate," "plan," "intend,"
"forecast," or other similar words. Statements contained in this press
release are based on information presently available to us and assumptions
that we believe to be reasonable. We are not assuming any duty to update this
information if those facts change or if we no longer believe the assumptions
to be reasonable. Investors are cautioned that all such statements involve
risks and uncertainties, including without limitation, statements concerning
building on our position as the leader in medical devices for epilepsy,
developing new medical devices incorporating cardiac-based detection of a
seizure, developing new and more efficacious medical devices for persons
suffering from epilepsy, and collaborating with Flint Hills Scientific on
research and product development. Our actual results may differ materially.
Important factors that may cause actual results to differ include, but are not
limited to: continued market acceptance of VNS Therapy(TM) and sales of our
product; the development and satisfactory completion of clinical trials and/or
market test and/or regulatory approval of VNS Therapy(TM) for the treatment of
other indications; satisfactory completion of post-market studies required by
the U.S. Food and Drug Administration as a condition of approval for the
treatment-resistant depression indication; adverse changes in coverage or
reimbursement amounts by third-parties; intellectual property protection and
potential infringement claims; maintaining compliance with government
regulations and obtaining necessary government approvals for new indications;
product liability claims and potential litigation; reliance on single
suppliers and manufacturers for certain components; the accuracy of
management's estimates of future expenses and sales; the results of the
previously disclosed governmental inquiries; the potential identification of
material weaknesses in our internal controls over financial reporting; risks
and costs associated with such governmental inquiries and any litigation
relating thereto or to our stock option grants, procedures, and practices and
other risks detailed from time to time in our filings with the Securities and
Exchange Commission (SEC). For a detailed discussion of these and other
cautionary statements, please refer to our most recent filings with the SEC,
including our Annual Report on Form 10-K for the fiscal year ended April 24,
2009.
CONTACT INFORMATION:
Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd., Houston, TX 77058
Main: (281) 228-7262/Fax: (281) 218-9332
ir@cyberonics.com
SOURCE Cyberonics, Inc.
Greg Browne, CFO of Cyberonics, Inc., +1-281-228-7262, Fax +1-281-218-9332,
ir@cyberonics.com
